Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Press Releases

Month Year

Month Year

Get News Alerts by Email

Jul 17, 2012

Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Jul 2, 2012

Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer

Study will compare detection of KRAS mutations in urine to their detection in biopsy samples
Jun 24, 2012

Trovagene to be Added to Russell Microcap Index
Jun 13, 2012

Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
Jun 6, 2012

Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
May 30, 2012

Trovagene, Inc. Announces Pricing of Public Offering of 1,150,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split
May 29, 2012

Trovagene, Inc. Announces Pricing of Public Offering of 1,150,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split
May 9, 2012

Trovagene, Inc., Announces Issuance of European Patent for Detection of Pathogenic Infections
May 1, 2012

Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
Apr 30, 2012

Dr. Carlo Croce joins Trovagene as Scientific Consultant and Member of the Company's Scientific Advisory Board

Internationally recognized cancer researcher and physician strengthens Trovagene's scientific expertise in cancer genetics
Apr 30, 2012

Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer

Company plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients
Apr 22, 2012

Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations

- Pharmaceutical and diagnostic sales and marketing executive will provide leadership to accelerate commercial programs -
Feb 26, 2012

Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.
Feb 13, 2012

Trovagene Appoints Charlie Rodi, Ph.D., as Chief Technology Officer
Feb 9, 2012

Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Feb 7, 2012

Trovagene Closes Acquisition of CLIA Laboratory Assets
Jan 5, 2012

TrovaGene Acquires CLIA - Certified Laboratory
Jan 2, 2012

TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia

License Complements Franchise of the Company's Proprietary Tumor Marker Assets in Hematological Cancers

Show per page